Clinical Trial Update: Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating lenalidomide after allogeneic hematopoietic cell transplant in AML and MDS patients with minimal residual disease; study terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: University of Florida | Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED | Results posted: 2020-01-13